nach oben

International Urology and Nephrology

Erschienen in:

14.08.2017 | Nephrology - Review

Elevated bilirubin levels and risk of developing chronic kidney disease: a dose–response meta-analysis and systematic review of cohort studies

verfasst von: Jun Wang, Peng Guo, ZhengYan Gao, BenGang Zhou, Lei Ren, Yu Chen, Quan Zhou

Erschienen in: International Urology and Nephrology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

Previous studies have indicated the link of bilirubin levels and risk of developing chronic kidney disease (CKD); however, the findings were inconsistent.

Methods

We searched for cohort studies examining bilirubin as an exposure and CKD as an outcome in the Medline, EMBASE, and Web of Science databases from inception through November 31, 2016. A generalized least-squares approach was applied to assess the dose–response relationship between them by pooling rate ratios with 95% confidence intervals. Subgroup analyses, sensitivity analysis, meta-regression, and publication bias were also conducted.

Results

Seven cohort studies with 1316 cases and 21,076 participants were identified for inclusion in the meta-analysis. The combined RR for the highest versus lowest bilirubin level was 0.36 (95% CI 0.19–0.68; P _{heterogeneity} = 0.001; Power = 0.72; n = 6). In the linear dose–response analysis, each 1-μmol/L increase in bilirubin was associated with a 5% reduced risk of CKD (RR = 0.95; 95% CI 0.92–0.97; P for trend test = 0.113; P _{heterogeneity} = 0.001; Power = 0.99; n = 7). The subgroup analyses and sensitivity analyses showed consistent results, and publication bias may exist.

Conclusion

This meta-analysis suggests that elevated bilirubin level may be associated with decreased risk of developing CKD.

Nur mit Berechtigung zugänglich

Said A, Desai C, Lerma EV (2015) Chronic kidney disease. Dis Mon DM 61(9):374–377. doi:10.1016/j.disamonth.2015.08.001 CrossRefPubMed

Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J (2012) Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308(22):2349–2360. doi:10.1001/jama.2012.16817 CrossRefPubMedPubMedCentral

GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117–171. doi:10.1016/S0140-6736(14)61682-2 CrossRef

Xu XM, Cai GY, Bu R, Wang WJ, Bai XY, Sun XF, Chen XM (2015) Beneficial effects of caloric restriction on chronic kidney disease in rodent models: a meta-analysis and systematic review. PLoS ONE 10(12):e0144442. doi:10.1371/journal.pone.0144442 CrossRefPubMedPubMedCentral

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. Lancet (London, England) 382(9888):260–272. doi:10.1016/s0140-6736(13)60687-x CrossRef

Fung E, Kurella Tamura M (2016) Epidemiology and public health concerns of CKD in older adults. Adv Chronic Kidney Dis 23(1):8–11. doi:10.1053/j.ackd.2015.10.001 CrossRefPubMedPubMedCentral

Turchetti G, Bellelli S, Amato M, Bianchi S, Conti P, Cupisti A, Panichi V, Rosati A, Pizzarelli F (2016) The social cost of chronic kidney disease in Italy. Eur J Health Econ HEPAC Health Econ Prev Care. doi:10.1007/s10198-016-0830-1

McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ (2017) Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. doi:10.1080/13696998.2017.1288127 PubMed

Huang FY, Peng Y, Huang BT, Yang Y, Pu XB, Chen SJ, Gui YY, Xia TL, Chen F, Liu RS, Zhu Y, Chen M (2016) The correlation between serum total bilirubin and outcomes in patients with different subtypes of coronary artery disease. Clin Chim Acta Int J Clin Chem 465:101–105. doi:10.1016/j.cca.2016.12.020 CrossRef

10.

Boon AC, Bulmer AC, Coombes JS, Fassett RG (2014) Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Ren Physiol 307(2):F123–F136CrossRef

11.

Huang SS, Huang PH, Wu TC, Chen JW, Lin SJ (2012) Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. PLoS ONE 7(8):e42594. doi:10.1371/journal.pone.0042594 CrossRefPubMedPubMedCentral

12.

Li JM, Shah AM (2003) ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol JASN 14(8 Suppl 3):S221–S226CrossRefPubMed

13.

Sharma K, Cook A, Smith M, Valancius C, Inscho EW (2005) TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Ren Physiol 288(5):F1069–F1077. doi:10.1152/ajprenal.00345.2004 CrossRef

14.

Thannickal VJ, Fanburg BL (1995) Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 270(51):30334–30338CrossRefPubMed

15.

Idelman G, Smith DL, Zucker SD (2015) Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase. Redox Biol 5:398–408. doi:10.1016/j.redox.2015.06.008 CrossRefPubMedPubMedCentral

16.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P(2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 2015

17.

Drewes HW, Steuten LM, Lemmens LC, Baan CA, Boshuizen HC, Elissen AM, Lemmens KM, Meeuwissen JA, Vrijhoef HJ (2012) The effectiveness of chronic care management for heart failure: meta-regression analyses to explain the heterogeneity in outcomes. Health Serv Res 47(5):1926–1959. doi:10.1111/j.1475-6773.2012.01396.x CrossRefPubMedPubMedCentral

18.

Wang J, Li Y, Han X, Hu H, Wang F, Yu C, Li X, Yang K, Yuan J, Yao P, Miao X, Wei S, Wang Y, Chen W, Liang Y, Zhang X, Guo H, Pan A, Yang H, Wu T, He M (2016) Association between serum bilirubin levels and decline in estimated glomerular filtration rate among patients with type 2 diabetes. J Diabetes Complicat 30(7):1255–1260CrossRefPubMed

19.

Tanaka S, Ninomiya T, Masutani K, Nagata M, Tsuchimoto A, Tsuruya K, Kitazono T (2015) Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy. Clin Exp Nephrol 19(6):1062–1070. doi:10.1007/s10157-015-1096-0 CrossRefPubMed

20.

Sakoh T, Nakayama M, Tanaka S, Yoshitomi R, Ura Y, Nishimoto H, Fukui A, Shikuwa Y, Tsuruya K, Kitazono T (2015) Association of serum total bilirubin with renal outcome in Japanese patients with stages 3–5 chronic kidney disease. Metab, Clin Exp 64(9):1096–1102. doi:10.1016/j.metabol.2015.06.006 CrossRef

21.

Chin HJ, Cho HJ, Lee TW, Na KY, Oh KH, Joo KW, Yoon HJ, Kim YS, Ahn C, Han JS, Kim S, Jeon ES, Jin DC, Kim YL, Park SH, Kim CD, Song YR, Kim SG, Kim YG, Lee JE, Oh YK, Lim CS, Lee SK, Chae DW, Cho WY, Kim HK, Jo SK (2009) The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci 24(Suppl):S22–S29. doi:10.3346/jkms.2009.24.S1.S22 CrossRefPubMedPubMedCentral

22.

Shin HS, Jung YS, Rim H (2011) Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults. BMC Nephrol 12:29. doi:10.1186/1471-2369-12-29 CrossRefPubMedPubMedCentral

23.

Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18(20):2693–2708CrossRefPubMed

24.

Nishimura T, Tanaka M, Sekioka R, Itoh H (2015) Serum bilirubin concentration is associated with eGFR and urinary albumin excretion in patients with type 1 diabetes mellitus. J Diabetes Complicat 29(8):1223–1227. doi:10.1016/j.jdiacomp.2015.07.007 CrossRefPubMed

25.

Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M (2009) Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Clin Chem Lab Med 47(9):1055–1062. doi:10.1515/cclm.2009.244 CrossRefPubMed

26.

Oda E, Aoyagi R, Aizawa Y (2012) Hypobilirubinemia might be a possible risk factor of end-stage kidney disease independently of estimated glomerular filtration rate. Kidney Blood Press Res 36(1):47–54. doi:10.1159/000339027 CrossRefPubMed

27.

Tanaka M, Fukui M, Okada H, Senmaru T, Asano M, Akabame S, Yamazaki M, Tomiyasu K, Oda Y, Hasegawa G, Toda H, Nakamura N (2014) Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 234(2):421–425. doi:10.1016/j.atherosclerosis.2014.03.015 CrossRefPubMed

28.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed

29.

Ryu S, Chang Y, Zhang Y, Woo HY, Kwon MJ, Park H, Lee KB, Son HJ, Cho J, Guallar E (2014) Higher serum direct bilirubin levels were associated with a lower risk of incident chronic kidney disease in middle aged Korean men. PLoS ONE 9(2):e75178. doi:10.1371/journal.pone.0075178 CrossRefPubMedPubMedCentral

30.

Hamling J, Lee P, Weitkunat R, Ambuhl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27(7):954–970. doi:10.1002/sim.3013 CrossRefPubMed

31.

Liu TZ, Xu C, Rota M, Cai H, Zhang C, Shi MJ, Yuan RX, Weng H, Meng XY, Kwong JS, Sun X (2017) Sleep duration and risk of all-cause mortality: a flexible, non-linear, meta-regression of 40 prospective cohort studies. Sleep Med Rev 32:28–36. doi:10.1016/j.smrv.2016.02.005 CrossRefPubMed

32.

Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119–1129CrossRefPubMed

33.

Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T (2011) Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ (Clin Res ed) 343:d6617. doi:10.1136/bmj.d6617 CrossRef

34.

Aune D, Norat T, Vatten LJ (2014) Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies. Eur J Nutr 53(8):1591–1601. doi:10.1007/s00394-014-0766-0 CrossRefPubMed

35.

Guo P, Huang G, Ren L, Chen Y, Zhou Q (2016) Number of parity and the risk of non-Hodgkin lymphomas: a dose-response meta-analysis of observational studies. Hematology. doi:10.1080/10245332.2016.1252002

36.

Orsini N, Bellocco R, Greenland S (2005) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6(1):40–57

37.

Orsini N (2013) Multivariate dose-response meta-analysis: An update on glst. Available at: http://www.stata.com/meeting/nordic-and-baltic13/abstracts. Accessed May 2015

38.

Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 175(1):66–73. doi:10.1093/aje/kwr265 CrossRefPubMed

39.

Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135(11):1301–1309CrossRefPubMed

40.

Crippa A, Orsini N (2016) Dose-response meta-analysis of differences in means. BMC Med Res Methodol 16:91. doi:10.1186/s12874-016-0189-0 CrossRefPubMedPubMedCentral

41.

Kazancioglu R (2013) Risk factors for chronic kidney disease: an update. Kidney Int Suppl 3(4):368–371. doi:10.1038/kisup.2013.79 CrossRef

42.

Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users’ guide to the medical literature. JAMA 311(4):405–411. doi:10.1001/jama.2013.285063 CrossRefPubMed

43.

Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from http://www.cochrane-handbook.org

44.

Doi SA, Barendregt JJ, Khan S, Thalib L, Williams GM (2015) Advances in the meta-analysis of heterogeneous clinical trials II: the quality effects model. Contemp Clin Trials 45(Pt A):123–129. doi:10.1016/j.cct.2015.05.010 CrossRefPubMed

45.

Doi SA, Barendregt JJ, Khan S, Thalib L, Williams GM (2015) Simulation comparison of the quality effects and random effects methods of meta-analysis. Epidemiology 26(4):e42–e44. doi:10.1097/ede.0000000000000289 CrossRefPubMed

46.

Doi SA, Thalib L (2008) A quality-effects model for meta-analysis. Epidemiology 19(1):94–100. doi:10.1097/EDE.0b013e31815c24e7 CrossRefPubMed

47.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRefPubMedPubMedCentral

48.

Hedges LV, Pigott TD (2001) The power of statistical tests in meta-analysis. Psychol Methods 6(3):203–217CrossRefPubMed

49.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

50.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186 CrossRefPubMed

51.

Sim J, Wright CC (2005) The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Therapy 85(3):257–268

52.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174CrossRefPubMed

53.

54.

Lee AT, Wang YY, Lin SY, Liang JT, Sheu WH, Song YM, Chang WD (2015) Higher serum total bilirubin concentration is associated with lower risk of renal insufficiency in an adult population. Int J Clin Exp Med 8(10):19212–19222PubMedPubMedCentral

55.

Jo J, Yun JE, Lee H, Kimm H, Jee SH (2011) Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population. Endocrine 39(2):182–189. doi:10.1007/s12020-010-9417-2 CrossRefPubMed

56.

Nakagami T, Toyomura K, Kinoshita T, Morisawa S (1993) A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin. Biochem Biophys Acta 1158(2):189–193CrossRefPubMed

57.

Song S, Wang S, Ma J, Yao L, Xing H, Zhang L, Liao L, Zhu D (2013) Biliverdin reductase/bilirubin mediates the anti-apoptotic effect of hypoxia in pulmonary arterial smooth muscle cells through ERK1/2 pathway. Exp Cell Res 319(13):1973–1987. doi:10.1016/j.yexcr.2013.05.015 CrossRefPubMed

58.

Sano K, Nakamura H, Matsuo T (1985) Mode of inhibitory action of bilirubin on protein kinase C. Pediatr Res 19(6):587–590CrossRefPubMed

59.

Fevery J (2008) Bilirubin in clinical practice: a review. Liver Int Off J Int Assoc Study Liver 28(5):592–605. doi:10.1111/j.1478-3231.2008.01716.x CrossRef

60.

Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ (2014) Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 63(8):2845–2853. doi:10.2337/db13-1652 CrossRefPubMed

61.

Lee MJ, Kwon S, Kim JH, Seo JY, Park SB, Nam YJ, Ahn KH, Jeon YK, Kim BH, Moon S, Chun SW, Kim IJ, Kim SS (2015) High serum bilirubin concentration predicts the progression of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function. Diabetes 64:A155–A156

62.

Han SS, Na KY, Chae DW, Kim YS, Kim S, Chin HJ (2010) High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 221(2):133–140CrossRefPubMed

63.

Katoh T, Kawamoto R, Kohara K, Miki T (2015) Association between serum bilirubin and estimated glomerular filtration rate among diabetic patients. Int Sch Res Notices 2015:480418. doi:10.1155/2015/480418 PubMedPubMedCentral

64.

Kawamoto R, Ninomiya D, Hasegawa Y, Kasai Y, Kusunoki T, Ohtsuka N, Kumagi T (2014) Association between serum bilirubin and estimated glomerular filtration rate among elderly persons. PLoS ONE 9(12):e115294. doi:10.1371/journal.pone.0115294 CrossRefPubMedPubMedCentral

65.

Kuriyama S, Maruyama Y, Nishio S, Takahashi Y, Kidoguchi S, Kobayashi C, Takahashi D, Sugano N, Hosoya T, Yokoo T (2015) Serum uric acid and the incidence of CKD and hypertension. Clin Exp Nephrol 19(6):1127–1134. doi:10.1007/s10157-015-1120-4 CrossRefPubMedPubMedCentral

66.

Liao WC, Tu YK, Wu MS, Lin JT, Wang HP, Chien KL (2015) Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ (Clin Res ed) 349:g7371. doi:10.1136/bmj.g7371

67.

Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB (2014) Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ (Clin Res ed) 349:g4490. doi:10.1136/bmj.g4490

68.

Yang WS, Va P, Wong MY, Zhang HL, Xiang YB (2011) Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. Am J Clin Nutr 94(6):1575–1583. doi:10.3945/ajcn.111.020966 CrossRefPubMedPubMedCentral

Titel: Elevated bilirubin levels and risk of developing chronic kidney disease: a dose–response meta-analysis and systematic review of cohort studies
verfasst von: Jun Wang
Peng Guo
ZhengYan Gao
BenGang Zhou
Lei Ren
Yu Chen
Quan Zhou
Publikationsdatum: 14.08.2017
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1675-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Effects of small molecules water that may retard kidney stone formation

Abdominal aorta and pelvic artery calcifications on plain radiographs may predict mortality in chronic kidney disease, hemodialysis and renal transplantation

Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI

Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies